



VIA REGISTERED POST AND EMAIL

Attention: Dr. Jagadeesh B Rangisetty,
Zenara Pharma Pvt Ltd
IDA Cherlapally, Hyderabad, 500051, India
Email: jrangisetty@biophore.com

Date: 5 June 2026

Re: Notice of Termination for the Molnupiravir Licence Agreement

Dear Dr. Rangisetty,

We refer to the licence agreement between the Medicines Patent Pool ("**MPP**") and Zenara Pharma Pvt Ltd ("**Licensee**") dated 8 February 2022 concerning patents and know-how pertaining to molnupiravir ("**Licence Agreement**").

MPP is entitled to terminate this Licence Agreement with immediate effect pursuant to Section 10.3(c) of the Licence Agreement, as the Licensee failed to comply with its obligations under Section 3.3, specifically the requirement to submit a complete file for WHO Prequalification or any SRA approval within thirty-six (36) months from the Effective Date (i.e. by 8 February 2025) for any existing formulation of the Products.

As such, please accept this letter as formal notice that MPP hereby terminates the Licence Agreement with immediate effect.



This termination is without prejudice to the surviving provisions of the Licence Agreement, including Sections 3A, 7.3, 8, 10.5, 11, and 12.

Sincerely,

For and on behalf of Medicines Patent Pool

A handwritten signature in black ink, appearing to be 'CP', is positioned above a horizontal line.

Name: Chan Park
Title: General Counsel
Date: 5 June 2026